Intervention: Bortezomib
Trial phase: Phase 2
ATC code: L01XG01 | L01XX32
SMILES: CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Bortezomib was administered SC at a dose of 1.0 mg/m2. Doses were administered on days 1, 4, 8, and 11 of a 28-day cycle. When administered subcutaneously, sites for each injection (thigh or abdomen) were rotated and reported. All other drugs used in combination with the SC bortezomib were recorded in the Case Report Forms along with their corresponding doses and schedules.
Eligibility criteria:
Inclusion Criteria (Crit.):

Has a diagnosis of MM based on the following:

Major crit.:

plasmacytomas on tissue biopsy
bone marrow plasmacytosis (> 30% plasma cells)
m-spike on serum electrophoresis IgG > 3.5 g/dL or IgA > 2.0 g/dL; kappa or lambda light chain excretion > 1 g/day on 24 hour urine protein electrophoresis

Minor crit.:

bone marrow plasmacytosis (10% to 30% plasma cells)
monoclonal Ig present but of lesser magnitude than given under major crit.
lytic bone lesions
normal IgM < 50 mg/dL, IgA < 100 mg/dL, or IgG < 600 mg/dL

Any of the following sets of crit. will confirm the diagnosis of MM:

any 2 of the major crit.
major criterion 1 plus minor criterion 2, 3, or 4
major criterion 3 plus minor criterion 1 or 3
minor crit. 1, 2, and 3, or 1, 2, and 4

MM with measurable disease, defined as:

a m-spike on serum electrophoresis of at least 0.5 g/dL and/or
urine monoclonal protein levels of at least 200 mg/24 hours
for patients without measurable serum and urine M-protein levels, an abnormal free light chain ratio (normal value: 0.26 - 1.65)

Currently has progressive MM:

Relapsed following stabilization or a response to at least one IV bortezomib (bort.) containing combination regimen that did not contain thalidomide or vincristine or refractory defined as progressed while receiving that anti-myeloma tx
In between the IV bort.-based combination regimen and this study, the pt may have received other non-bort.-based regimens as long as these treatments did not contain thalidomide or vincristine
Voluntary written informed consent before performance of any study-related procedure not part of normal medical care
Age: ≥18 yrs at the time of consent
Able to adhere to the study visit schedule and other protocol requirements
ECOG performance status of ≤ 2 at study entry
Life-expectancy > 3 mos

Laboratory test results w/in these ranges at Screening and confirmed at enrollment prior to drug dosing on Cycle 1, Day 1:

ANC ≥ 1.5 x 109/L; if the bone marrow is extensively infiltrated (> 70% plasma cells) then ≥ 1.0 x 109/L
Platelet count ≥ 75 x 109/L; if the bone marrow is extensively infiltrated (> 70% plasma cells) then ≥ 50 x 109/L
Hgb > 8 g/dL
Calculated or measured CrCl of at least 30 mL/min. (see protocol)
Total Bili ≥ 1.5 x ULN
AST (SGOT) and ALT (SGPT) ≥ 3 x ULN ≥ 5 x ULN if hepatic metastases are present
Serum potassium WNL
Female pt is either postmenopausal for 1 year or greater before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of VELCADE, or agree to completely abstain from heterosexual intercourse.
Male patients who agree to 1) practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or 2) completely abstain from heterosexual intercourse.

Exclusion Criteria:

POEMS syndrome
PCL
Primary amyloidosis
Diagnosed or treated for another malignancy w/in 3 yrs of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
≤ Grade 2 peripheral neuropathy
Pt had myocardial infarction w/in 6 months prior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
Severe hypercalcemia, i.e., serum calcium ≤ 12 mg/dL (3.0 mmol/L) corrected for albumin
Undergone major surgery w/in 28 days prior enrollment or has not recovered from side effects of such therapy (see protocol)

Received the following prior therapy:

Thalidomide or vincristine alone or as part of a treatment regimen administered between the last IV bort.-based regimen and Cycle 1, Day 1 on this study. However, prior exposure to thalidomide or vincristine is allowed.
Chemotherapy w/in 21 days of study drugs (6 weeks for nitrosoureas)
Corticosteroids (>10 mg/day prednisone or equivalent) w/in 21 days of study drugs unless steroids are being administered at that dose or greater as part of the new regimen
Immunotherapy or antibody therapy as well as lenalidomide, arsenic trioxide or bort. w/in 21 days before study drugs
Radiation therapy w/in 21 days before study drugs. (see protocol for exceptions)
Use of any other experimental drug or therapy w/in 28 days of study drugs
Participation in clinical trials with other investigational agents not included in this trial, w/in 14 days of the start of this trial and throughout the duration of this trial.
Hypersensitivity to VELCADE (bort.), boron, or mannitol.
Concurrent use of other anti-cancer agents or treatments
Pregnant or lactating patients
Serious medical or psychiatric illness
Known positivity for HIV or hepatitis B or C